Regeneron Pharmaceuticals Inc. said on Thursday the company would buy the global rights to the cancer drug Libtayo from French drugmaker Sanofi SA in a deal that includes an upfront payment of $900 million.
https://www.pharmalive.com/wp-content/uploads/2022/03/Sanofi-shares-drop-on-trial-setback-for-breast-cancer-pill-Reuters-3-14-22.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-06-02 08:35:542022-06-02 11:41:31Regeneron buys rights to cancer drug Libtayo from Sanofi